Is Titan Biotech overvalued or undervalued?

As of 11 July 2025, Titan Biotech's valuation grade has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently considered overvalued. Key ratios include a PE ratio of 17.74, an EV to EBITDA of 14.92, and a Price to Book Value of 2.49, which suggest that the stock is trading at a premium compared to its earnings and book value.
In comparison to its peers, Titan Biotech's PE ratio is notably lower than Solar Industries, which has a PE of 115.16, and significantly higher than Godrej Industries, which stands at 37.69. This places Titan in a challenging position within the specialty chemicals sector, as it appears less attractive relative to these competitors. Additionally, while the stock has underperformed on a year-to-date basis with a decline of 36.88%, it has shown strong performance over the long term, with a 5-year return of 530.97%, which may not fully justify its current valuation.